Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway

Figure 5

Sp1 and c-Myc activated survivin transcription in LSCs. (A) Chromatin immune-precipitation was used to analyze the binding of Sp1 and c-Myc to the survivin promoter. Input was used as a positive control. (B) ChIP-qPCR was used to confirm the results shown in (A) (** P < 0.01). (C) Transcription activities of survivin was analyzed following over-expression of Sp1 and c-Myc vector in KG-1a and MOLM13-LSCs (* P < 0.05). The cells were co-transfected with the pcDNA-survivin vector, core promoter V5, and Renilla luciferase plasmid as a control. Cells were also treated with MITA to analyze the effects of Sp1 inhibition on survivin promoter activity. (D) Specific siRNA-Sp1/c-Myc was performed to assess the effects of these two motifs on survivin luciferase activities. (E) Survivin protein levels were analyzed in LSCs following treatment with MITA at 50, 100, or 200 nM. (F) ChIP assays were used to determine whether MITA could directly inhibit Sp1 and c-Myc binding to its specific sites. All data are shown as the means ± SDs of results from three experiments.

Back to article page